Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.30 |
| ▸ | CDC25B | P30305 | 3/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25435703 | 0.83 | ALDH1A1 (0.36) | NT5ELMNAALDH1A1CYP2D6MAPK1 | |
| SCHEMBL19492149 | 0.83 | ALDH1A1 (0.36) | NT5ELMNAALDH1A1CYP2D6MAPK1 | |
| SCHEMBL30689540 | 0.80 | ALDH1A1 (0.35) | NT5ELMNAPTPN1CDC25BALDH1A1 | |
| SCHEMBL16648568 | 0.78 | — | — | |
| SCHEMBL20394059 | 0.76 | BCHE (0.39) | LMNAPTPN1CDC25BALDH1A1CYP2D6 | |
| SCHEMBL30590064 | 0.75 | LMNA (0.39) | NT5ELMNAALDH1A1CYP2D6MAPK1 | |
| SCHEMBL19101763 | 0.75 | LMNA (0.39) | NT5ELMNAALDH1A1CYP2D6MAPK1 | |
| SCHEMBL26121971 | 0.75 | LMNA (0.39) | NT5ELMNAALDH1A1CYP2D6MAPK1 | |
| SCHEMBL20756448 | 0.74 | ALDH1A1 (0.37) | NT5ELMNAALDH1A1CYP2D6MAPK1 | |
| SCHEMBL23152976 | 0.74 | ALDH1A1 (0.37) | NT5ELMNAALDH1A1CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862868-B1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-9738681-B2 | Intermediate for production of nucleoside analog and method for producing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862868-A1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | KLK7 2233/4885KLK5 2472/4885NT5E 183/4885 |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | KLK7 2233/4885KLK5 2472/4885NT5E 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.